相关实验视频

Updated: May 28, 2025

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

[ tixagevimab/cilgavimab在患有血液性瘤的患者的预防疗效:单中心研究]

Hirofumi Nakano¹, Shiori Nakashima¹, Yui Imai¹

¹Department of Hematology, Eiju General Hospital.

[Rinsho ketsueki] The Japanese journal of clinical hematology

|February 9, 2025

概括

在患有血液学疾病的患者中,tixagevimab/cilgavimab (Tix/Cil) 对COVID-19的疗效有限. 一种抗Tix/Cil的Omicron变种导致突破性感染的增加,使得Tix/Cil在预防中变得无效.

科学领域:

免疫学免疫学免疫学
病毒学病毒学
血液学血液学血液学

背景情况:

提克萨吉维玛/西尔加维玛 (Tix/Cil) 用于COVID-19的治疗和预防.
血液学疾病代表了一个易受严重感染的脆弱人群.
评估Tix/Cil在这个群体中的实际有效性至关重要.

研究的目的:

评估Tix/Cil在患有血液学疾病的患者中的疗效.
调查新出现的SARS-CoV-2变种对Tix/Cil有效性的影响.
确定目前在这个患者群体中预防COVID-19的建议.

主要方法:

追溯分析了142名患有血液学疾病的患者,他们接受了Tix/Cil.
在11名患者中对Omicron变异的全基因组测序.
在Tix/Cil耐药变种占主导地位之前和之后的突破性感染率的比较.

主要成果:

Tix/Cil的疗效有限,9.5%的患者感染了COVID-19,其中3人治疗后仍感染.
恶性淋巴瘤和多发性骨髓瘤是最常见的潜在疾病.
整个基因组测序显示,仅在2名患者 (中度COVID-19严重程度) 中,Omicron变种对Tix/Cil的敏感性.
在2023年4月以后,Tix/Cil耐药变种 (>70%) 与突破性感染率从4%上升到35%相关,没有对Tix/Cil.反应.

结论:

蒂克萨吉维马布/西尔加维马布在患有血液学疾病的患者中不再有效用于COVID-19预防,这是由于广泛的变体耐药性.
疫苗接种和日常预防措施是预防高风险人群中COVID-19的推策略,特别是那些患有淋巴细胞恶性瘤的人群.
耐药SARS-CoV-2变种的出现需要持续监测和治疗和预防方法的适应.

关键词:

在 COVID-19 疫情中,血液学的新生体.预防预防预防提克萨吉维玛布/西尔加维玛布

更多相关视频

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...